Certara's AI-Driven Pharma Surge

Certara, led by CEO Jon Resnick, celebrates its 100-day milestone with a strong focus on model-informed drug development (MIDD). The company reported Q1 revenue of $106.9 million, with software sales surging 7% and services dipping 4%. They divested their medical writing business, streamlining operations and aiming for steady growth. Certaras simulation tools, like Simcyp and Pinnacle twenty-one, are in high demand due to increased AI usage in drug discovery and recent FDA approvals. The company boasts an impressive track record, with over 2,600 customers and 36 trillion data points validated for 500+ approvals. In an effort to capitalize on AI trends, Certara is reorganizing into MID3 and ACE divisions, appointing a new Chief AI Officer, and partnering with NVIDIA. Software bookings surged 20%, net retention reached 106%, and full-year guidance remains at $395-$405 million, flat to 4% growth excluding divestiture. Certara is well-positioned to leverage AI advancements in pharma, transforming decades of expertise into scalable solutions for faster patient treatments. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/cbcbcd2f4168b4ee